What is it about?
Covers various controversial matters in clinical trials.
Featured Image
Why is it important?
Discusses issues to do with blinding, multi-centre trials, comprehensive cohort studies, cutoff designs and cross-over trials versus parallel group trials. Discusses the issue of representativeness and comes to the conclusion it is less important than often supposed.
Read the Original
This page is a summary of: A personal view of some controversies in allocating treatment to patients in clinical trials, Statistics in Medicine, December 1995, Wiley,
DOI: 10.1002/sim.4780142406.
You can read the full text:
Contributors
The following have contributed to this page
